Cut-off determination of HLA crossmatching by flow cytometry
Article Sidebar
Main Article Content
Abstract
Background: Microlymphocytotoxicity test is a gold standard for HLA crossmatching but provides low sensitivity. Emerging flow cytometry crossmatching (FCXM) provides more sensitivity, however, suitable cut-off values for FCXM must still be established for crossmatching result interpretation.
Objectives: This study aimed to determine the appropriate cut-off value for FCXM in kidney transplant patients and donors.
Materials and methods: A total of 30 sample pairs with known HLA typing and known antibody specificity were analyzed. Median channel fluorescence (MCF) and median channel fluorescence shift (MFS) were used to determine cut-off value using three different approaches and % accuracy was determined.
Results: The result showed that the cut-off values from first approach using lowest MCF of positive control and highest MCF of negative control were 1655.99 MCF for T-cells (yielding 100% accuracy) and 43668.06 MCF for B-cells (yielding 36.67% accuracy). The cut-off values from second approach which calculated from standard deviation (SD) of negative control MCF showed SD of T-cells MCF as 203.81 (100% accuracy) and SD for B-cells MCF as 11109.30 (60% accuracy). The cut-off values from third approach derived from the lowest MFS of the expected positive results were 1753.50 for T-cells (100% accuracy) and 593.50 for B-cells (73.33% accuracy).
Conclusion: The cut-off values from the third approach exhibited the highest accuracy. However, FCXM still had false positives and false negatives, underscoring the necessity for continuous refinement and adjustment of cut-off values based on the data accumulated within the laboratory to be used further for routine laboratory practice.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Personal views expressed by the contributors in their articles are not necessarily those of the Journal of Associated Medical Sciences, Faculty of Associated Medical Sciences, Chiang Mai University.
References
Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010; 77(4): 299-311.
Paul A, Dileep RCA, Gracious N. Crossmatch and Histocompatibility. Int J Open Inf Technol. 2024. doi: 10.5772/intechopen.1006348.
Fuggle SV, Taylor CJ. Chapter 10 - Histocompatibility in renal transplantation. In: Morris PJ, Knechtle SJ, Editors. Kidney transplantation. 6th Ed. Philadelphia: WB Saunders; 2008. pp: 140-57. doi: 10.1016/B978-1-4160-3343-1.50014-1.
Kupatawintu P, Tatawatorn A, Premasathian N, Avihingsanon Y, Leelahavanichkul A, Hirankarn N. Association between flow cytometric crossmatching and graft survival in Thai cadaveric-donor kidney transplantation. Asian Pac J Allergy Immunol. 2016; 34(1): 86-93. doi: 10.12932/ap0569.34.1.2016.
Lao-araya M. Flow cytometry in medical research and clinical applications. Biomed Sci Clin Med. 2014; 53(2): 99-109.
Park Y, Kim HS. P140 Proper setting of cut-off value for the lymphocyte crossmatch by flow cytometry in kidney transplantation. Hum Immunol. 2018; 79-165. doi: 10.1016/j.humimm.2018.07.197.
Chamsai S, Kittisares K, Thanaketpaisarn Y, Ngamthawornwong S, Koktathong K. Evaluation of the three-colored flow cytometric crossmatch assay in living-related kidney transplantation. J Hematol Transfus Med. 2018; 28: 239-48.
Dispao T. Comparison of HLA crossmatching results between microlymphocytotoxicity test and flow cytometry in kidney transplant patients [Term paper]. Faculty of Associated Medical Science: Chiang Mai University; 2023. [in Thai].
Choktaweesak N. Flow cytometric crossmatch: an alternative technique of HLA compatibility testing in deceased donor kidney transplant waitedlist [Thesis]. Faculty of Allied Health Sciences: Chulalongkorn University; 2020 [in Thai].
de Moraes P, Fagundes I, Cardone JM, Gil BC, Kulzer ASS, Hadi RA, et al. Accuracy of the median channel shift in the flow cytometry for predicting complement dependent cytotoxicity crossmatching in kidney transplant candidates. Transpl Immunol. 2019; 52: 27-31. doi: 10.1016/j.trim.2018.10.005.
Guillaume N. Improved flow cytometry crossmatching in kidney transplantation. HLA. 2018; 92(6): 375-83. doi: 10.1111/tan.13403.
Liwski RS, Gebel HM. Of cells and microparticles: assets and liabilities of HLA antibody detection. Transplantation. 2018; 102(1S): S1-S6. doi: 10.1097/tp.0000000000001818.
Holdsworth R, Hurley CK, Marsh SGE, Lau M, Noreen HJ, Kempenich JH, et al. The HLA dictionary 2008: a summary of HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. Tissue Antigens. 2009; 73(2):95-170. doi: 10.1111/j.1399-0039.2008.01183.x.
Park BG, Park Y, Joo DJ, Huh KH, Kim MS, Kim SI, et al. Clinical significance of donor-specific anti-HLADR51/52/53 antibodies for antibody-mediated rejection in kidney transplant recipients. Korean J Transplant. 2019; 33(3): 47-54. doi: 10.4285/jkstn.2019.33.3.47.
Brian JF, Rosanne P, Cynthia DF, Tricia C, Shari S, Candy V, et al. Abrogating biologics interference in flow cytometric crossmatching. Hum Immunol. 2021; 82(8): 574-80. doi: 10.1016/j.humimm. 2021.01.016.
Downing J. The lymphocyte crossmatch by flow cytometry for kidney transplantation. In: Christiansen FT, Tait BD, editors. Immunogenetics: methods and applications in clinical practice. Totowa, NJ: Humana Press; 2012. p. 379-90. doi: 10.1007/ 978-1-61779-842-9_22.
Koktathong K, Vejbaesya S, Bejrachandra S, Pattanapanyasat K. Flow cytometric crossmatch for kidney transplantation. J Med Assoc Thai. 2005; 88: 769-74.
Sarah JH, Karl PS, Andrea AZ, Annette MJ. Impact of pronase on flow cytometric crossmatch outcome. Hum Immunol. 2011; 74(4): 330-6. doi: 10.1016/j.humimm.2011.01.005.
Cláudia S, Paula A, Paula S, Paula X. Low expression loci and the use of pronase in flow cytometry crossmatch. Transplant Proc. 2023; 55(6): 1389-9.
Liwski RS, Greenshields AL, Conrad DM, Murphey C, Bray RA, Neumann J, Gebel HM. Rapid optimized flow cytometric crossmatch (FCXM) assays: the Halifax and Halifaster protocols. Hum Immunol. 2018; 79(1): 28-38. doi: 10.1016/j.humimm. 2017.10.020.
Moszkowska G, Zieliński M, Zielińska H, Dukat-Mazurek A, Dębska-Zielkowska J, Dębska-Ślizień A, et al. Evaluation of pretransplant donor-specific alloantibodies with different crossmatch techniques. Transplant Proc. 2018: 50(6): 1625-30. doi: 10.1016/j.transproceed.2018.02.165.
